LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...
Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results